Aliases & Classifications for Myoma

MalaCards integrated aliases for Myoma:

Name: Myoma 12 55 44 15 73
Neoplasms, Muscle Tissue 44 73
Muscle Benign Neoplasm 12 15
Myomatous Neoplasm 12 73
Benign Neoplasm of the Muscle 12
Muscle Tissue Neoplasm 12
Neoplasm of Muscle 12
Muscle Neoplasm 12
Myomatous Tumor 12

Classifications:



Summaries for Myoma

MalaCards based summary : Myoma, also known as neoplasms, muscle tissue, is related to adenomyosis and benign metastasizing leiomyoma, and has symptoms including muscle cramp, muscle rigidity and muscle spasticity. An important gene associated with Myoma is PGR (Progesterone Receptor), and among its related pathways/superpathways is Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics. The drugs Dimenhydrinate and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include uterus, bone and lung, and related phenotypes are cellular and homeostasis/metabolism

Wikipedia : 76 Myoma is a kind of mesenchymal... more...

Related Diseases for Myoma

Diseases related to Myoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
# Related Disease Score Top Affiliating Genes
1 adenomyosis 31.4 ESR1 PGR
2 benign metastasizing leiomyoma 30.6 CYP19A1 PGR
3 endometrial stromal sarcoma 30.5 CYP19A1 ESR1 PGR
4 endometriosis 30.4 CYP19A1 ESR1 GNRH1 PGR
5 leiomyomatosis 30.3 ESR1 GNRH1 MED12 PGR
6 endometriosis of uterus 30.1 GNRH1 HPSE2
7 polycystic ovary syndrome 30.0 CYP19A1 GNRH1 LEP
8 infertility 29.9 CYP19A1 GNRH1 PGR
9 leiomyoma 29.1 CYP19A1 ESR1 GNRH1 HMGA2 MED12 PGR
10 breast fibroadenoma 28.9 CYP19A1 ESR1 HMGA2 MED12 PGR
11 skeletal muscle cancer 11.1
12 dartoic leiomyoma 11.1
13 carney complex variant 10.9
14 vulvar syringoma 10.9 ESR1 PGR
15 lung leiomyoma 10.9 ESR1 PGR
16 vestibular gland benign neoplasm 10.9 ESR1 PGR
17 bartholin's gland adenoma 10.9 ESR1 PGR
18 glassy cell carcinoma of the cervix 10.9 ESR1 PGR
19 vulvar benign neoplasm 10.9 ESR1 PGR
20 trigonitis 10.9 ESR1 PGR
21 vulvar leiomyoma 10.9 ESR1 PGR
22 predominantly cortical thymoma 10.9 ESR1 PGR
23 muscle cancer 10.8
24 mixed endometrial stromal and smooth muscle tumor 10.8
25 breast medullary carcinoma 10.8 ESR1 PGR
26 breast scirrhous carcinoma 10.8 ESR1 PGR
27 progesterone resistance 10.8 ESR1 PGR
28 bizarre leiomyoma 10.8 MED12 PGR
29 cribriform carcinoma 10.8 ESR1 PGR
30 oncocytic breast carcinoma 10.8 ESR1 PGR
31 endometrial squamous cell carcinoma 10.8 ESR1 PGR
32 gastric signet ring cell adenocarcinoma 10.8 ESR1 PGR
33 endometrial mucinous adenocarcinoma 10.8 ESR1 PGR
34 adenoid basal cell carcinoma 10.8 ESR1 PGR
35 apocrine adenocarcinoma 10.8 ESR1 PGR
36 hypertensive encephalopathy 10.8 CYP19A1 EPO
37 bartholin's gland benign neoplasm 10.8 ESR1 PGR
38 deep angioma 10.7 ESR1 PGR
39 synchronous bilateral breast carcinoma 10.7 ESR1 PGR
40 breast adenoid cystic carcinoma 10.7 ESR1 PGR
41 cervical carcinosarcoma 10.7 ESR1 PGR
42 intramuscular hemangioma 10.7 ESR1 PGR
43 glycogen-rich clear cell breast carcinoma 10.7 ESR1 PGR
44 uterus leiomyosarcoma 10.7
45 retinitis pigmentosa 47 10.7 ESR1 PGR
46 uterine corpus cancer 10.7 ESR1 PGR
47 progesterone-receptor positive breast cancer 10.6 CYP19A1 ESR1 PGR
48 gender identity disorder 10.6 CYP19A1 ESR1 PGR
49 estrogen excess 10.6 CYP19A1 ESR1 PGR
50 retinitis pigmentosa 20 10.6 ESR1 PGR

Graphical network of the top 20 diseases related to Myoma:



Diseases related to Myoma

Symptoms & Phenotypes for Myoma

UMLS symptoms related to Myoma:


muscle cramp, muscle rigidity, muscle spasticity, myoclonus, torticollis, muscle weakness, myalgia

MGI Mouse Phenotypes related to Myoma:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.16 CYP19A1 EPO ESR1 CD3E XRCC4 PGR
2 homeostasis/metabolism MP:0005376 10.13 CYP19A1 GNRH1 HPSE2 EPO ESR1 XRCC4
3 hematopoietic system MP:0005397 10.11 CYP19A1 GNRH1 EPO ESR1 CD3E XRCC4
4 endocrine/exocrine gland MP:0005379 10.08 CYP19A1 GNRH1 LEP ESR1 CD3E OXT
5 immune system MP:0005387 10.06 CYP19A1 GNRH1 EPO ESR1 CD3E XRCC4
6 digestive/alimentary MP:0005381 10.04 CYP19A1 GNRH1 HPSE2 LEP ESR1 OXT
7 integument MP:0010771 10.02 CYP19A1 GNRH1 EPO LEP ESR1 CD3E
8 mortality/aging MP:0010768 10.02 HPSE2 EPO ESR1 CD3E MED12 XRCC4
9 neoplasm MP:0002006 9.73 GNRH1 LEP ESR1 CD3E XRCC4 PGR
10 renal/urinary system MP:0005367 9.7 CYP19A1 GNRH1 HPSE2 LEP ESR1 OXT
11 reproductive system MP:0005389 9.5 CYP19A1 GNRH1 ESR1 XRCC4 OXT PGR
12 skeleton MP:0005390 9.23 CYP19A1 GNRH1 EPO LEP ESR1 PGR

Drugs & Therapeutics for Myoma

Drugs for Myoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 406)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dimenhydrinate Approved Phase 4 523-87-5 441281
2
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 1,Phase 2 9004-61-9 53477741
3
Dienogest Approved Phase 4 65928-58-7
4
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
5
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 4 62-90-8 229455
6
Desogestrel Approved Phase 4 54024-22-5 40973
7
Goserelin Approved Phase 4,Phase 3 65807-02-5 47725 5311128
8
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
9
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
10
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 57-27-2 5288826
11
Calcium Carbonate Approved, Investigational Phase 4,Phase 3 471-34-1
12
Zinc oxide Approved Phase 4 1314-13-2
13
Anastrozole Approved, Investigational Phase 4,Phase 3 120511-73-1 2187
14
Letrozole Approved, Investigational Phase 4,Phase 2,Phase 1 112809-51-5 3902
15
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 137-58-6 3676
16
Dinoprostone Approved Phase 4,Not Applicable 363-24-6 5280360
17
Misoprostol Approved Phase 4,Phase 3,Phase 2 59122-46-2 5282381
18
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
19
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 44475014
20
Zinc Approved, Investigational Phase 4 7440-66-6 23994
21
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
22
Acetaminophen Approved Phase 4,Phase 1 103-90-2 1983
23
Ibuprofen Approved Phase 4,Not Applicable 15687-27-1 3672
24
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
25
Ethanol Approved Phase 4,Not Applicable 64-17-5 702
26
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53714-56-0 3911 657181
27
Mifepristone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 84371-65-3 55245
28
Levonorgestrel Approved, Investigational Phase 4,Not Applicable 797-63-7, 17489-40-6 13109
29
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 57-83-0 5994
30
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 50-02-2 5743
31
Nitrous oxide Approved, Vet_approved Phase 4,Not Applicable 10024-97-2 948
32
Tranexamic Acid Approved Phase 4 1197-18-8 5526
33
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
34
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
35
Glycine Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 56-40-6 750
36
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
37
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
38
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
39
leucovorin Approved, Nutraceutical Phase 4,Phase 2 58-05-9 143 6006
40
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4 13422-55-4
41
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 1 59-67-6 938
42
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 1 98-92-0 936
43
Pyridoxal Approved, Nutraceutical Phase 4 66-72-8 1050
44
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
45
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
46
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130
47
Tocopherol Approved, Investigational, Nutraceutical Phase 4 1406-66-2 14986
48
Vitamin C Approved, Nutraceutical Phase 4,Phase 3 50-81-7 5785 54670067
49
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
50
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985

Interventional clinical trials:

(show top 50) (show all 555)
# Name Status NCT ID Phase Drugs
1 Seprafilm Slurry in the Prevention of Uterine Scarring in Patients Undergoing Hysteroscopic Myomectomy Unknown status NCT01632202 Phase 4
2 IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure Unknown status NCT02601196 Phase 4 Ulipristal acetate
3 Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women Unknown status NCT02440750 Phase 4 Dienogest;Ulipristal acetate
4 Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin Unknown status NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
5 High Intensity Focused Ultrasound Ablation Virus Myomectomy to Treat Uterine Fibroids Unknown status NCT01239641 Phase 4
6 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
7 Pilot of Letrozole for Uterine Myomas Completed NCT02470741 Phase 4 Letrozole
8 Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators Completed NCT00743080 Phase 4
9 Intravenous or Intra-abdominal Local Anesthetics for Postoperative Pain Management. Completed NCT01492179 Phase 4 Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine
10 Single Versus Double Dose Intra-vaginal Prostaglandin E2 "Misoprostol" Prior Abdominal Myomectomy Completed NCT02154932 Phase 4 2 doses 400 microgram misoprostol;single dose misoprostol
11 Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial Completed NCT01393704 Phase 4 Vasopressin
12 Morphine vs. Oxycodone for Postoperative Pain Management Completed NCT00528177 Phase 4 Morphine and oxycodone
13 The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids. Completed NCT00995878 Phase 4
14 SIGnificance of Routine Hysteroscopy Prior to a First 'in Vitro Fertilization'(IVF) Treatment Cycle Completed NCT01242852 Phase 4
15 Fibroids in Women of Reproductive Age and Women Pregnancy Completed NCT02620345 Phase 4 Dydrogesterone M ( case 1 );Dydrogesterone M ( case 2 )
16 Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization Completed NCT02293447 Phase 4 Lidocaine per-embolization;Lidocaine post-embolization
17 Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids Completed NCT00746031 Phase 4 GnRH analogue (Zoladex);GnRH antagonist-Cetrorelix
18 Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women With Uterine Fibroids Wishing to Pursue Pregnancy in the Future Completed NCT00180739 Phase 4
19 Efficacy Study of Magnetic Resonance (MR) Guided Focused Ultrasound in the Treatment of Large Fibroids Completed NCT00159328 Phase 4
20 Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
21 A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
22 Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery Completed NCT01388907 Phase 4
23 Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas Recruiting NCT02361905 Phase 4 ulipristal acetate;Leuprolide acetate
24 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Recruiting NCT02361879 Phase 4 ulipristal acetate;Leuprolide acetate
25 Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis Recruiting NCT03500367 Phase 4 rapamycin
26 Ulipristal Acetate Versus GnRH Analogue and Myometrial Preservation Recruiting NCT02357563 Phase 4 ulipristal acetate;Leuprolide acetate
27 A Study on the Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy Recruiting NCT03210324 Phase 4 Mifepristone tablets
28 Aromatase Plus GnRH Analogue Versus Ulippristal Acetate in Uterine Fibroids Recruiting NCT03421639 Phase 4 Ulipristal acetate;Aromatase inhibitor plus GnRH analog
29 Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids Recruiting NCT03317795 Phase 4 Levonorgestrel IUS;Tranexamic Acid
30 Misoprostol for Reduction of Blood Loss During Fibroid Surgery Recruiting NCT02209545 Phase 4 Misoprostol;Placebo
31 Ulipristal Use in Chinese Population Active, not recruiting NCT02825719 Phase 4 Ulipristal acetate;Ferrous sulphate;Tranexamic Acid
32 Peritoneal Cavity Conditioning Decreases Pain, Inflammation and Adhesions Terminated NCT01344486 Phase 4
33 Preemptive Analgesia Following Uterine Artery Embolization Terminated NCT01555073 Phase 4 pregabalin/celecoxib;pregabalin/placebo;celecoxib/placebo;Placebo group
34 Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy Unknown status NCT01483417 Phase 3
35 Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
36 Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01048931 Phase 3
37 The Use of Doppler to Diagnose Myometrial Masses Unknown status NCT01833871 Phase 2, Phase 3
38 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
39 Study of Tumor-shrinking Decoction (TSD) to Treat Symptomatic Uterine Fibroids Unknown status NCT02189083 Phase 3 TSD
40 Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy Unknown status NCT01280045 Phase 3
41 PGL4001 Versus GnRH-agonist in Uterine Myomas Completed NCT00740831 Phase 3 PGL4001;leuprorelin
42 PGL4001 Versus Placebo in Uterine Myomas Completed NCT00755755 Phase 3 PGL4001 (ulipristal) and iron;PGL4001 matching placebo and iron;PGL4001 (ulipristal) and iron
43 Barbed Suture in Single-port Laparoscopic Myomectomy Completed NCT01984632 Phase 3
44 Vasopressin Versus Epinephrine in Myomectomy Completed NCT01861015 Phase 3 Epinephrine;Vasopressin
45 Study on the Effect of Intravenous Ascorbic Acid on Intraoperative Blood Loss in Women With Uterine Myoma Completed NCT01715597 Phase 3 ascorbic acid;Normal saline
46 PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata Completed NCT01642472 Phase 3 Ulipristal Acetate - open label
47 PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata Completed NCT01156857 Phase 3 PGL4001, placebo;PGL4001, progestin
48 PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study) Completed NCT01252069 Phase 3 PGL4001, placebo, drug free period;PGL4001, progestin, drug free period
49 Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy Completed NCT01064128 Phase 3
50 PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata Completed NCT01629563 Phase 3 PGL4001 5 mg;PGL4001 10 mg

Search NIH Clinical Center for Myoma

Cochrane evidence based reviews: myoma

Genetic Tests for Myoma

Anatomical Context for Myoma

MalaCards organs/tissues related to Myoma:

41
Uterus, Bone, Lung, T Cells, Testes, Nk Cells, Smooth Muscle

Publications for Myoma

Articles related to Myoma:

(show top 50) (show all 610)
# Title Authors Year
1
The uterine fibroid/myoma tumour: analysis of the global research architecture using density-equalizing mapping. ( 29198424 )
2018
2
Acute intestinal obstruction due to extrinsic compression by previa myoma and ectopic pregnancy: a case report. ( 29335010 )
2018
3
Transvaginal Natural Orifice Transluminal Endoscopic Surgery Myomectomy: A Novel Route for Uterine Myoma Removal. ( 29410143 )
2018
4
Recurrence of uterine myoma after myomectomy: Open myomectomy versus laparoscopic myomectomy. ( 29227004 )
2018
5
Modern Myoma Treatment in the Last 20 Years: A Review of the Literature. ( 29789793 )
2018
6
Expression and prognostic value of lactate dehydrogenase-A and -D subunits in human uterine myoma and uterine sarcoma. ( 29620641 )
2018
7
The expression of MA1llerian inhibiting substance/anti-MA1llerian hormone type II receptor in myoma and adenomyosis. ( 29372159 )
2018
8
Dehiscence of a Low Transverse Cesarean Scar by a Submucous Myoma in a Nongravid Uterus. ( 29709694 )
2018
9
Ulipristal Acetate Improves Clinical Symptoms in Women with Adenomyosis and Uterine Myomas. ( 29626678 )
2018
10
Matrix metalloproteinase activity correlates with uterine myoma volume reduction after ulipristal acetate treatment. ( 29408988 )
2018
11
Diagnosis and treatment of submucous myoma of the uterus with interventional ultrasound. ( 29616100 )
2018
12
Multimodal imaging for diagnosis and management of parasitic peritoneal myoma with myxoid degeneration after laparoscopic-assisted myomectomy with electric power morcellation. ( 29516586 )
2018
13
Morbidity, fertility and pregnancy outcomes after myoma enucleation by laparoscopy versus laparotomy. ( 29417281 )
2018
14
Multidisciplinary Approach in Large Sized Submucosal Myoma: Hysteroscopic Myomectomy after Uterine Artery Embolization. ( 29969685 )
2018
15
Dynamic thiol/disulphide homeostasis in patients with Uterine Myoma. ( 28697394 )
2017
16
Minimally Invasive Approaches to Myoma Management. ( 28734973 )
2017
17
Impact of pelvic magnetic resonance imaging findings in the indication of uterine artery embolization in the treatment of myoma. ( 28397200 )
2017
18
OUTCOME OF PREGNANCY WITH CLINICALLY VISIBLE/PALPABLE MYOMA AMONG WOMEN WHO UNDERGO CAESARIAN SECTION IN THREE TEACHING HOSPITALS, ADDIS ABABA, ETHIOPIA: A CROSS SECTIONAL STUDY. ( 29148636 )
2017
19
Psychiatric outcomes after hysterectomy in women with uterine myoma: a population-based retrospective cohort study. ( 28597115 )
2017
20
Unexpected uterine leiomyosarcoma in a woman with multiple myomas treated with ulipristal acetate: case report and literature review. ( 28933575 )
2017
21
Pilot Study of the Mirabilis System Prototype for Rapid Noninvasive Uterine Myoma Treatment Using an Ultrasound-Guided Volumetric Shell Ablation Technique. ( 28109895 )
2017
22
Falsely Elevated Postvoid Residual Urine Volume in Uterine Myoma. ( 28503470 )
2017
23
Sacral Schwannoma Mimicking a Myoma Uterus. ( 28132872 )
2017
24
Pregnancy Outcomes After Direct Uterine Myoma Thermal Ablation: Review of the Literature. ( 28109894 )
2017
25
Unique Learning System for Uterine Artery Embolization for Symptomatic Myoma and Adenomyosis for Obstetrician-Gynecologists in Cooperation with Interventional Radiologists: Evaluation of UAE From the Point of View of Gynecologists Who Perform UAE. ( 28807810 )
2017
26
Myomectomies for massive hemoperitoneum from spontaneous bleeding of a uterine myoma. ( 28852453 )
2017
27
Increased risk of breast cancer in women with uterine myoma: a nationwide, population-based, case-control study. ( 28382798 )
2017
28
Urethrovaginal fistula following vaginal prolapse of a pedunculated uterine myoma: a case report. ( 29058627 )
2017
29
May-Thurner syndrome caused by a huge uterine myoma. ( 29296055 )
2017
30
Quality assessment of pelvic ultrasound for uterine myoma according to the CNGOF guidelines. ( 28643658 )
2017
31
Alcohol consumption and risk of uterine myoma: A systematic review and meta analysis. ( 29176884 )
2017
32
Novel management of a giant cervical myoma in a premenopausal patient. ( 28993358 )
2017
33
Incidence of Malignancy and Myoma Variants at Surgery for Presumed Benign Symptomatic Myomas. ( 28216458 )
2017
34
Myoma and myomectomy: Poor evidence concern in pregnancy. ( 28892210 )
2017
35
Rewriting the script: time to rethink the indications for myoma surgery. ( 28069179 )
2017
36
Myoma in Septic Necrobiosis at 10 Days Post-Partum. ( 29102219 )
2017
37
Laparoscopy or laparotomy as the way of entrance in myoma enucleation. ( 28819682 )
2017
38
Total laparoscopic hysterectomy for large uterine cervical myoma. ( 28515917 )
2017
39
A Lumbosacral Plexopathy Compressed by Huge Uterine Myoma. ( 29076826 )
2017
40
Endometrial flushing I+VI^3 integrin, glycodelin and PGF2I+ levels for evaluating endometrial receptivity in women with polycystic ovary syndrome, myoma uteri and endometrioma. ( 28454508 )
2017
41
Myoma-associated pain frequency and intensity: a retrospective evaluation of 1548 myoma patients. ( 26930041 )
2016
42
Parasitic Myomas and an Adenomyoma Obstructing the Ureter After Power Morcellation of Myomas and Endometriotic Nodule Resection. ( 27208606 )
2016
43
Cigarette smoking and risk of uterine myoma: systematic review and meta-analysis. ( 26706924 )
2016
44
Uncommon Complication of Uterine Artery Embolization: Expulsion of Infarcted Myoma and Uterine Sepsis. ( 27073705 )
2016
45
Laparoscopic management of huge myoma nascendi. ( 27632930 )
2016
46
Myoma migration: an unexpected "effect" with Ulipristal acetate treatment. ( 27160112 )
2016
47
The Unintended Consequences of an FDA Warning: The Case of Power Morcellation in Myoma Surgery. ( 26898893 )
2016
48
Torsion of a parasitic myoma that developed after abdominal myomectomy. ( 26866042 )
2016
49
PARASITIC MYOMA AS AN ADNEXAL MASS: UNEXPECTED FINDING AFTER VAGINAL HYSTERECTOMY. ( 28394545 )
2016
50
Ex abundanti cautela: From the tragedy of inadvertent sarcoma morcellation to inappropriate myoma screening. ( 27226785 )
2016

Variations for Myoma

Expression for Myoma

Search GEO for disease gene expression data for Myoma.

Pathways for Myoma

Pathways related to Myoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.23 CYP19A1 ESR1

GO Terms for Myoma

Biological processes related to Myoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.81 EPO GNRH1 LEP OXT
2 signal transduction GO:0007165 9.76 EPO ESR1 GNRH1 HMGA2 LEP OXT
3 transcription initiation from RNA polymerase II promoter GO:0006367 9.7 ESR1 MED12 PGR
4 stem cell differentiation GO:0048863 9.54 ESR1 HMGA2
5 response to estradiol GO:0032355 9.54 ESR1 LEP OXT
6 female pregnancy GO:0007565 9.5 GNRH1 LEP OXT
7 eating behavior GO:0042755 9.49 LEP OXT
8 response to electrical stimulus GO:0051602 9.48 EPO OXT
9 intracellular steroid hormone receptor signaling pathway GO:0030518 9.46 ESR1 MED12
10 androgen metabolic process GO:0008209 9.43 CYP19A1 ESR1
11 response to nutrient GO:0007584 9.43 CD3E EPO LEP
12 uterus development GO:0060065 9.4 CYP19A1 ESR1
13 response to prostaglandin E GO:0034695 8.96 GNRH1 OXT
14 ovulation from ovarian follicle GO:0001542 8.62 LEP PGR

Molecular functions related to Myoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.92 EPO GNRH1 LEP OXT

Sources for Myoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....